These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 24925048)
1. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Broadhead GK; Hong T; Chang AA Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048 [TBL] [Abstract][Full Text] [Related]
2. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958 [TBL] [Abstract][Full Text] [Related]
3. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. Teo KYC; Gillies M; Fraser-Bell S Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632 [TBL] [Abstract][Full Text] [Related]
4. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Schachat AP Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369 [No Abstract] [Full Text] [Related]
5. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. Cheung GCM; Lai TYY; Gomi F; Ruamviboonsuk P; Koh A; Lee WK Asia Pac J Ophthalmol (Phila); 2017; 6(6):527-534. PubMed ID: 28971633 [TBL] [Abstract][Full Text] [Related]
7. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal? Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373 [TBL] [Abstract][Full Text] [Related]
8. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679 [TBL] [Abstract][Full Text] [Related]
9. Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Lois N; McBain V; Abdelkader E; Scott NW; Kumari R Retina; 2013 Jan; 33(1):13-22. PubMed ID: 22846802 [TBL] [Abstract][Full Text] [Related]
14. [Clarifying some concepts and clinical significance of refractory or recurrent neovascular age-related macular degeneration]. Zhao J; Sun X Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):804-7. PubMed ID: 26850580 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725 [TBL] [Abstract][Full Text] [Related]
16. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838 [TBL] [Abstract][Full Text] [Related]
17. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Finger RP; Guymer RH; Gillies MC; Keeffe JE Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613 [TBL] [Abstract][Full Text] [Related]
18. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021 [TBL] [Abstract][Full Text] [Related]
19. Does laser still have a role in the management of retinal vascular and neovascular diseases? Shah AM; Bressler NM; Jampol LM Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309 [TBL] [Abstract][Full Text] [Related]
20. [Compliance of age related macular degeneration patients undergoing anti-VEGF therapy : Analysis and suggestions for improvement]. Heimes B; Gunnemann F; Ziegler M; Gutfleisch M; Spital G; Pauleikhoff D; Lommatzsch A Ophthalmologe; 2016 Nov; 113(11):925-932. PubMed ID: 27272633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]